drugset / Trial / NCT00068172
Study of PI-88 in Patients With Advanced Melanoma
Phase 1/2
Completed
88 enrolled
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether PI-88 is safe and effective in the treatment of advanced melanoma.
Timeline
- Start
- 2001-07
- Primary completion
- 2007-06
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | muparfostat | Other / unclassified | — | Subcutaneous |